Stoke Therapeutics Inc (STOK) FinancialsSTOKStoke Therapeutics Inc

Evaluating the bottom line, Stoke Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -701.65%, while the net margin is -660.78%. These profitability ratios, combined with a Return on Equity (ROE) of -61.10%, provide a clear picture of how effectively STOK converts its operational activities into shareholder value.

In the context of the broader market, STOK competes directly with industry leaders such as QURE and KRSA. With a market capitalization of $1.50B, it holds a significant position in the sector. When comparing efficiency, STOK's gross margin of 100.00% stands against QURE's 94.01% and KRSA's N/A. Such benchmarking helps identify whether Stoke Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Stoke Therapeutics reported a Q2 2026 revenue of $9.33 million, a 32.4% decline year-over-year, and a GAAP EPS of -$0.93, missing expectations by $0.15. The gross margin remains strong at 100%, but net income continues to be negative, indicating ongoing financial struggles.